XBiotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for XBiotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XBiotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGS:XBIT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	N/A	-33	-29	-28	N/A
6/30/2024	N/A	-35	-25	-23	N/A
3/31/2024	N/A	-31	-22	-21	N/A
12/31/2023	N/A	-25	-19	-19	N/A
9/30/2023	0	-23	-19	-18	N/A
6/30/2023	2	-28	-19	-18	N/A
3/31/2023	4	-31	-15	-15	N/A
12/31/2022	4	-33	-15	-15	N/A
9/30/2022	8	-36	-14	-13	N/A
6/30/2022	11	-27	-17	-16	N/A
3/31/2022	14	-20	59	63	N/A
12/31/2021	18	-17	66	69	N/A
9/30/2021	19	-13	66	71	N/A
6/30/2021	25	-12	76	82	N/A
3/31/2021	36	-14	-7	-3	N/A
12/31/2020	44	-11	-69	-65	N/A
9/30/2020	39	677	-70	-69	N/A
6/30/2020	28	673	-82	-81	N/A
3/31/2020	13	674	-75	-74	N/A
12/31/2019	N/A	669	-18	-18	N/A
9/30/2019	N/A	-24	-20	-20	N/A
6/30/2019	N/A	-23	-19	-19	N/A
3/31/2019	N/A	-23	-18	-18	N/A
12/31/2018	N/A	-21	-17	-17	N/A
9/30/2018	N/A	-22	-19	-18	N/A
6/30/2018	N/A	-23	N/A	-21	N/A
3/31/2018	N/A	-27	N/A	-25	N/A
12/31/2017	N/A	-33	N/A	-34	N/A
9/30/2017	N/A	-42	N/A	-40	N/A
6/30/2017	N/A	-49	N/A	-48	N/A
3/31/2017	N/A	-53	N/A	-48	N/A
12/31/2016	N/A	-53	N/A	-46	N/A
9/30/2016	N/A	-48	N/A	-44	N/A
6/30/2016	N/A	-47	N/A	-36	N/A
3/31/2016	N/A	-40	N/A	-37	N/A
12/31/2015	N/A	-37	N/A	-33	N/A
9/30/2015	N/A	-32	N/A	-26	N/A
6/30/2015	N/A	-28	N/A	-22	N/A
3/31/2015	N/A	-25	N/A	-16	N/A
12/31/2014	N/A	-22	N/A	-12	N/A
9/30/2014	N/A	-18	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XBIT's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if XBIT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if XBIT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if XBIT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if XBIT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XBIT's Return on Equity is forecast to be high in 3 years time

XBiotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies